Together with physicians, other research groups, and industry partners, Fraunhofer MEVIS is developing software to optimize radiation therapy. The fifth clinical workshop to evaluate this software took place in Bremen on Feb. 5-6.

Researchers at the University of California Los Angeles (UCLA) have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.

New research from Johns Hopkins School of Medicine reveals a high value for scans which could lead to future change of reimbursement policies for follow-up positron emission tomography/computed tomography (PET/CT) studies in lung cancer. The study, featured in the February 2015 issue of The Journal of Nuclear Medicine, establishes the value of fourth and subsequent follow-up PET/CT scans in clinical assessment and management change in patients with the disease.

Pie Medical Imaging BV announced that it received 510(k) clearance from the U.S. Food and Drug Administration for its CAAS A-Valve product including the quantitative Regurgitation Analysis (qRA) workflow. The qRA workflow is the first 510(k) cleared image analysis technology to determine aortic regurgitation based on X-ray angiography.

Agfa Healthcare announced the commercial launch of its Enterprise Imaging for Cardiology Suite and strategic relationship with TomTec to provide a unified cardiology diagnostic and clinical imaging solution. The solution will be on display at the American College of Cardiology (ACC) 2015 meeting, March 14-16, 2015 in San Diego.

Enterprise Imaging for Cardiology Suite

A pilot study led by researchers at Joslin Diabetes Center has revealed that it is possible to use magnetic resonance imaging (MRI) to "see" the inflammation in the pancreas that leads to type 1 diabetes. This discovery could be a boon for research on methods to slow or halt the disease at an early stage, and could also guide insights into how diabetes progresses.

The Mevion S250 proton therapy system has become the first proton therapy system to receive a medical device license from Health Canada, the federal department responsible for public health, and is now approved to be installed at cancer facilities across the country.

Mobius Medical Systems LP announced the release of Mobius3D version 1.5. For users with the MobiusFX treatment verification module, the newest version of Mobius3D automatically verifies accurate delivery of every fraction in a patient’s course of treatment.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now